Brief: Abbvie Closes In On Nearly $11Bn Deal For Biotech Apogee Therapeutics - FT
BRIEF-Abbvie Closes In On Nearly $11Bn Deal For Biotech Apogee Therapeutics - FT June 19 (Reuters) - ABBVIE CLOSES IN ON NEARLY $11BN DEAL FOR BIOTECH APOGEE THERAPEUTICS - FT
UNDER THE TERMS OF THE DEAL BEING DISCUSSED, ABBVIE WOULD PAY APOGEE SHAREHOLDERS $10.9BN IN CASH - FT
ABBVIE'S DEAL FOR FOR BIOTECH APOGEE THERAPEUTICS IS EXPECTED TO BE ANNOUNCED AS SOON AS MONDAY -FT
: ABBVIE CLOSES IN ON NEARLY $11BN DEAL FOR BIOTECH APOGEE THERAPEUTICS - FT
Source text: [ID:]
Further company coverage: ABBV.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Apogee Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Abbvie Seeks At Least $8 Billion In Debt To Fund Apogee Deal - Bloomberg News
Street View: Strength in AbbVie's immunology pipeline to support revenue growth
AbbVie trims 2026 profit view on Apogee deal, tops second-quarter estimates (updated)